Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press1910.17650/2313-805X.2014.1.2.4-15REVIEWОБЗОРЫModern strategies for study of tumor’s markers in clinical practicСовременные стратегии исследования маркеров опухолевого роста в клинической практикеZborovskayaI. B.ЗборовскаяИ. Б.
Russian Federation
zborovskaya@mail.ruScientific Research Institute of Carcinogenesis, N. N. Blokhin Russian Cancer Research Center, Russia, 115478, Moscow, Kashirskoye shosse, 24Научно-исследовательский институт канцерогенеза ФГБНУ «Российский онкологический научный центр им. Н. Н. Блохина», Россия, 115478, Москва, Каширское шоссе, 24N. N. Blokhin Russian Cancer Research Center, Russia, 115478, Moscow, Kashirskoye shosse, 24ФГБНУ «РОНЦ им. Н. Н. Блохина», Россия, 115478, Москва, Каширское шоссе, 2415052014124150206201502062015Copyright ©; 2014, Zborovskaya I.B.Copyright ©; 2014, Зборовская И.Б.2014Zborovskaya I.B.Зборовская И.Б.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/19

Importance of molecular genetics-based essays in clinical oncology is now unquestionable due to the fact that all oncological diseases and their progression are based on cascading accumulation of genetic aberrations involving more than 20 different genes. Essentially new capacities of clinical oncology are uncovered with the help of modern molecular biology methods that allow to determine structural and functional changes of genes and their products. This review examines approaches to improve criteria for creating diagnostic essays, evaluation of treatment efficiency and molecular factors of clinical course. In order to determine relevant markers, special consideration should be given to the research of signal transduction pathways involving key genes responsible for tumor growth and their partners. The correct formation of patient’s groups and selection of samples is very important. It is emphasized that integrated clinical programs should combine traditional methods of diagnostics and treatment with modern molecular testing and bioinformatics methods.

oncomarkerssignaling pathwaysgermline mutationsallelic polymorphismmicroRNADNA methylationpolyadenylationsplicingtranscriptomtumor stem cellsонкомаркерысигнальные путигерминальные мутацииаллельный полиморфизммикроРНКметилирование ДНКполиаденилированиесплайсингтранскриптомстволовые клетки опухоли1. Sato M., Shames D. S., Gazdar A. F., Minna J. D. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007;2(4):327–43.Sato M., Shames D. S., Gazdar A. F., Minna J. D. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007;2(4):327–43.2. Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–74.Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–74.3. Langley R. R., Fidler I. J. The seed and soil hypothesis revisited – the role of tumorstroma interactions in metastasis to different organs. Int J Cancer 2011;128(11):2527–35.Langley R. R., Fidler I. J. The seed and soil hypothesis revisited – the role of tumorstroma interactions in metastasis to different organs. Int J Cancer 2011;128(11):2527–35.4. Копнин Б. П. Современные представления о механизмах злокачественного роста: сходства и различия солидных опухолей и лейкозов. Клиническая онкогематология 2012;5(3):165–83. [Kopnin B.P. Modern conceptions of malignant growth mechanisms: imilarities and differences of solid tumors and leukosis. Klinicheskaya onkogematologiya = inical Oncohematology 2012;5(3):165–83. (In Russ.)]Копнин Б. П. Современные представления о механизмах злокачественного роста: сходства и различия солидных опухолей и лейкозов. Клиническая онкогематология 2012;5(3):165–83. [Kopnin B.P. Modern conceptions of malignant growth mechanisms: imilarities and differences of solid tumors and leukosis. Klinicheskaya onkogematologiya = inical Oncohematology 2012;5(3):165–83. (In Russ.)]5. McAllisster S.S., Weinberg R. A. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 2014;16(8):717–27.McAllisster S.S., Weinberg R. A. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 2014;16(8):717–27.6. Verma M., Manne U. Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. Crit Rev Oncol Hematol 2006;60(1):9–18.Verma M., Manne U. Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. Crit Rev Oncol Hematol 2006;60(1):9–18.7. Thomas R. K., Baker A. C., Debiasi R. M. et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007;39(3):347–51.Thomas R. K., Baker A. C., Debiasi R. M. et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007;39(3):347–51.8. Hesson L. B., Hitchins M. P., Ward R. L. Epimutations and cancer predisposition: importance and mechanisms. Curr Opin Genet Dev 2010;20(3):290–8.Hesson L. B., Hitchins M. P., Ward R. L. Epimutations and cancer predisposition: importance and mechanisms. Curr Opin Genet Dev 2010;20(3):290–8.9. Peltomäki P. Mutations and epimutations in the origin of cancer. Exp Cell Res 2012;318(4):299–310.Peltomäki P. Mutations and epimutations in the origin of cancer. Exp Cell Res 2012;318(4):299–310.10. Suzuki H., Yamamoto E., Maruyama R. et al. Biological significance of the CpG island methylator phenotype. Biochem Biophys Res Commun 2014. pii: S0006-291X(14)01221–2. doi: 10.1016 / j. bbrc.2014.07.007.Suzuki H., Yamamoto E., Maruyama R. et al. Biological significance of the CpG island methylator phenotype. Biochem Biophys Res Commun 2014. pii: S0006-291X(14)01221–2. doi: 10.1016 / j. bbrc.2014.07.007.11. Shames D. S., Minna J. D., Gazdar A. F. DNA methylation in health, disease, and cancer. Curr Mol Med 2007;7(1):85–102.Shames D. S., Minna J. D., Gazdar A. F. DNA methylation in health, disease, and cancer. Curr Mol Med 2007;7(1):85–102.12. Киселева Н. П., Киселев Ф. Л. Эпигенетическая регуляция экспрессии генов в вирусссоциированных опухолях человека. Успехи молекулярной онкологии 2014;(1):48–55. [Kiseleva N. P., Kiselev F. L. Epygenetic regulation of gene expression in virus-associated human tumors. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2014;(1):48–55. (In Russ.)].Киселева Н. П., Киселев Ф. Л. Эпигенетическая регуляция экспрессии генов в вирусссоциированных опухолях человека. Успехи молекулярной онкологии 2014;(1):48–55. [Kiseleva N. P., Kiselev F. L. Epygenetic regulation of gene expression in virus-associated human tumors. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2014;(1):48–55. (In Russ.)].13. Tam W., Weinberg R. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013;19(11):1438–49.Tam W., Weinberg R. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013;19(11):1438–49.14. Curinha A., Braz S. O., Pereira-Castro I. et al. Implications of polyadenylation in health and disease. Nucleus 2014;5(6). PMID: 25191751.Curinha A., Braz S. O., Pereira-Castro I. et al. Implications of polyadenylation in health and disease. Nucleus 2014;5(6). PMID: 25191751.15. Wennerberg K., Rossman K. L., Der C. J. The Ras superfamily at a glance. J Cell Sci 2005;118(Pt 5):843–6.Wennerberg K., Rossman K. L., Der C. J. The Ras superfamily at a glance. J Cell Sci 2005;118(Pt 5):843–6.16. Hanahan D., Coussens L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21(3):309–22.Hanahan D., Coussens L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21(3):309–22.17. Недоспасов С. А., Купраш Д. В. Цитокины, их рецепторы и передача внутриклеточных сигналов. В кн.: Канцерогенез. Под ред. Д. Г. Заридзе. М.: Медицина, 2004. С. 158–68. [Nedospasov S.A., Kuprash D.V. Cytokines, their receptors, and intracellular signal transfer. In: Carcinogenesis. D.G. Zaridze (ed.). Moscow: Medicine, 2004. Pp. 158–68. (In Russ.)]Недоспасов С. А., Купраш Д. В. Цитокины, их рецепторы и передача внутриклеточных сигналов. В кн.: Канцерогенез. Под ред. Д. Г. Заридзе. М.: Медицина, 2004. С. 158–68. [Nedospasov S.A., Kuprash D.V. Cytokines, their receptors, and intracellular signal transfer. In: Carcinogenesis. D.G. Zaridze (ed.). Moscow: Medicine, 2004. Pp. 158–68. (In Russ.)]18. Gorovetz M., Baekelandt M., Berner A. et al. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. Gynecol Oncol 2006;103(3): 831–40.Gorovetz M., Baekelandt M., Berner A. et al. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. Gynecol Oncol 2006;103(3): 831–40.19. Gelman I. H. The role of SSeCKS / gravin / AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development. Front Biosci 2002;7: d1782–97.Gelman I. H. The role of SSeCKS / gravin / AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development. Front Biosci 2002;7: d1782–97.20. Zhang B., Wang J., Wang X. et al. Proteogenomic characterization of human colon and rectal cancer. Nature 2014;513(7518):382–7.Zhang B., Wang J., Wang X. et al. Proteogenomic characterization of human colon and rectal cancer. Nature 2014;513(7518):382–7.21. Arkhipova K. A., Zborovskaya I. B. Microdomain-forming proteins of different families in common signal pathways. Biologicheskie Membrany 2013;29(6): 387–99.Arkhipova K. A., Zborovskaya I. B. Microdomain-forming proteins of different families in common signal pathways. Biologicheskie Membrany 2013;29(6): 387–99.22. Глушанкова Н. А., Житняк И. Ю., Айолло Д. В., Рубцова С. Н. Роль Е-кадхерина в неопластической эволюции эпителиальных клеток. Успехи молекулярной онкологии 2014;(1):12–7. [Gloushankova N. A., Zhitnyak I. Yu., Ayollo D. V., Rubtsova S. N. The role of cadherin in neoplastic evolution of epithelial cells. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2014;(1):12–7. (In Russ.)].Глушанкова Н. А., Житняк И. Ю., Айолло Д. В., Рубцова С. Н. Роль Е-кадхерина в неопластической эволюции эпителиальных клеток. Успехи молекулярной онкологии 2014;(1):12–7. [Gloushankova N. A., Zhitnyak I. Yu., Ayollo D. V., Rubtsova S. N. The role of cadherin in neoplastic evolution of epithelial cells. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2014;(1):12–7. (In Russ.)].23. Gupta R., Toufaily C., Annabi B. Caveolin and cavin family members: Dual roles in cancer. Biochimie 2014. pii: S0300–9084(14) 00259–4. doi: 10.1016 / j. biochi. 2014.09.010.Gupta R., Toufaily C., Annabi B. Caveolin and cavin family members: Dual roles in cancer. Biochimie 2014. pii: S0300–9084(14) 00259–4. doi: 10.1016 / j. biochi. 2014.09.010.24. Santarpia L., Nicoloso M., Calin G. A. MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. Endocr Relat Cancer 2010;17(1):51–75.Santarpia L., Nicoloso M., Calin G. A. MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. Endocr Relat Cancer 2010;17(1):51–75.25. White N. M., Fatoohi E., Metias M. et al. Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol 2011;8(2):75–84.White N. M., Fatoohi E., Metias M. et al. Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol 2011;8(2):75–84.26. Lee S. K., Calin G. A. Non-coding RNAs and cancer: new paradigms in oncology. Discov Med 2011;11(58):245–54.Lee S. K., Calin G. A. Non-coding RNAs and cancer: new paradigms in oncology. Discov Med 2011;11(58):245–54.27. Takahashi R., Miyazaki H., Ochiya T. The role of microRNAs in the regulation of cancer stem cells. Front Genet 2014;4:295. doi: 10.3389 / fgene. 2013.00295.Takahashi R., Miyazaki H., Ochiya T. The role of microRNAs in the regulation of cancer stem cells. Front Genet 2014;4:295. doi: 10.3389 / fgene. 2013.00295.28. Gupta P. B., Chaffer C. L., Weinberg R. A. Cancer stem cells: mirage or reality? Nat Med 2009;15(9):1010–2.Gupta P. B., Chaffer C. L., Weinberg R. A. Cancer stem cells: mirage or reality? Nat Med 2009;15(9):1010–2.29. Krutovskikh V., Partensky C. New insights in oncology: epigenetics and cancer stem cells. Cancer Radiother 2011;15(8):716–22.Krutovskikh V., Partensky C. New insights in oncology: epigenetics and cancer stem cells. Cancer Radiother 2011;15(8):716–22.30. Mannelli G., Gallo O. Cancer stem cells hypothesis and stem cells in head and neck cancers. Cancer Treat Rev 2012;38(5):515–39.Mannelli G., Gallo O. Cancer stem cells hypothesis and stem cells in head and neck cancers. Cancer Treat Rev 2012;38(5):515–39.31. Aushev V. N., Zborovskaya I. B., Laktionov K. K. et al. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS One 2013;8(10):e78649. doi: 10.1371 / journal. pone. 0078649.Aushev V. N., Zborovskaya I. B., Laktionov K. K. et al. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS One 2013;8(10):e78649. doi: 10.1371 / journal. pone. 0078649.32. Ishida M., Selaru F. M. miRNA-based therapeutic strategies. Curr Anesthesiol Rep 2013;1(1):63–70.Ishida M., Selaru F. M. miRNA-based therapeutic strategies. Curr Anesthesiol Rep 2013;1(1):63–70.33. Mäbert K., Cojoc M., Peitzsch C. et al. Cancer biomarker discovery: current status and future perspectives. Int J Radiat Biol 2014;90(8):659–77.Mäbert K., Cojoc M., Peitzsch C. et al. Cancer biomarker discovery: current status and future perspectives. Int J Radiat Biol 2014;90(8):659–77.34. Volinia S., Nuovo G., Drusco A. et al. Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. J Natl Cancer Inst 2014;106(12). pii: dju324. doi: 10.1093 / jnci / dju324.Volinia S., Nuovo G., Drusco A. et al. Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. J Natl Cancer Inst 2014;106(12). pii: dju324. doi: 10.1093 / jnci / dju324.35. Имянитов Е. Н., Хансон К. П. Молекулярная онкология: клинические аспекты. СПб.: Издательский дом СПбМАПО, 2007. 212 с. [Imaynitov E.N., Hanson C.P. Molecular oncology: clinicalaspects. St. Petersburg: SPbMAPO Publishing House, 2007. 212 p. (In Russ.)]Имянитов Е. Н., Хансон К. П. Молекулярная онкология: клинические аспекты. СПб.: Издательский дом СПбМАПО, 2007. 212 с. [Imaynitov E.N., Hanson C.P. Molecular oncology: clinicalaspects. St. Petersburg: SPbMAPO Publishing House, 2007. 212 p. (In Russ.)]36. Goode E. L., Ulrich C. M., Potter J. D. Polymorphisms in DNA repair genes and ssociations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11(12):1513–30.Goode E. L., Ulrich C. M., Potter J. D. Polymorphisms in DNA repair genes and ssociations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11(12):1513–30.37. Timofeeva M. N., Hung R. J., Rafnar T. et al. Influence of common genetic variation on lungcancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet 2012;21(22):4980–95.Timofeeva M. N., Hung R. J., Rafnar T. et al. Influence of common genetic variation on lungcancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet 2012;21(22):4980–95.38. Sosa M. S., Bragado P., Aguirre-Ghiso J. A. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 2014;14(9):611–22.Sosa M. S., Bragado P., Aguirre-Ghiso J. A. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 2014;14(9):611–22.39. Suvà M. L., Riggi N., Bernstein B. E. Epigenetic reprogramming in cancer. Science 2013;339(6127):1567–70.Suvà M. L., Riggi N., Bernstein B. E. Epigenetic reprogramming in cancer. Science 2013;339(6127):1567–70.40. Marjanovic N. D., Weinberg R. A., Chaffer C. L. Poised with purpose: cell plasticity enhances tumorigenicity. Cell Cycle 2013;12(17):2713–9.Marjanovic N. D., Weinberg R. A., Chaffer C. L. Poised with purpose: cell plasticity enhances tumorigenicity. Cell Cycle 2013;12(17):2713–9.41. Красильников М. А., Щербаков А. Н. Сигнальные пути, регулируемые эстрогенами, и их роль в опухолевой прогрессии: новые факты и направления поиска. Успехи молекулярной онкологии 2014;(1):18–26. [Krasil’nikov M.A., Shcherbakov A. M. Estrogen-dependent signaling pathways and their role in the tumor progression: progress and perspectives. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2014; 1):18–26. (In Russ.)].Красильников М. А., Щербаков А. Н. Сигнальные пути, регулируемые эстрогенами, и их роль в опухолевой прогрессии: новые факты и направления поиска. Успехи молекулярной онкологии 2014;(1):18–26. [Krasil’nikov M.A., Shcherbakov A. M. Estrogen-dependent signaling pathways and their role in the tumor progression: progress and perspectives. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2014; 1):18–26. (In Russ.)].42. Сергеева Н. С., Маршутина Н. В., Солохина М. П. и др. Современные представления о серологических опухолеассоциированных маркерах и их месте в онкологии. Успехи молекулярной онкологии 2014;(1):69–80. [Sergeeva N. S., Marshutina N. V., Solokhina M. P. et al. Modern conceptions of serological tumor markers and their role in oncology. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2014;(1):69–80. (In Russ.)].Сергеева Н. С., Маршутина Н. В., Солохина М. П. и др. Современные представления о серологических опухолеассоциированных маркерах и их месте в онкологии. Успехи молекулярной онкологии 2014;(1):69–80. [Sergeeva N. S., Marshutina N. V., Solokhina M. P. et al. Modern conceptions of serological tumor markers and their role in oncology. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2014;(1):69–80. (In Russ.)].43. Denholm R., Schüz J., Straif K. et al. Is previous respiratory disease a risk factor for lung cancer? Am J Respir Crit Care Med 2014;190(5):549–59.Denholm R., Schüz J., Straif K. et al. Is previous respiratory disease a risk factor for lung cancer? Am J Respir Crit Care Med 2014;190(5):549–59.44. Taioli E., Gaspari L., Benhamou S. et al. Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. Int J Epidemiol 2003;32(1):60–3.Taioli E., Gaspari L., Benhamou S. et al. Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. Int J Epidemiol 2003;32(1):60–3.45. Fidler I. J. Biological heterogeneity of cancer: implication to therapy. HumVaccin Immunother 2012;8(8):1141–2.Fidler I. J. Biological heterogeneity of cancer: implication to therapy. HumVaccin Immunother 2012;8(8):1141–2.46. Zborovskaya I., Gasparian A., Karseladze A. et al. Somatic genetic alterations(LOH) in benign, borderline and invasive ovarian tumours: intratumoral molecular heterogeneity. Int J Cancer 1999;82(6):822–6.Zborovskaya I., Gasparian A., Karseladze A. et al. Somatic genetic alterations(LOH) in benign, borderline and invasive ovarian tumours: intratumoral molecular heterogeneity. Int J Cancer 1999;82(6):822–6.47. Gupta P. B., Fillmore C. M., Jiang G. et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011;46(4):633–44.Gupta P. B., Fillmore C. M., Jiang G. et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011;46(4):633–44.48. Подгорный О. В., Лазарев В. Н., Говорун В. М. Лазерная микродиссекция в биологии и медицине. Цитология 2012;54(5):381–9. [Podgornyi O.V., Lazarev V.N., Govorun V.M. Laser dissection in biology and medicine. Tsitologiya = Cytology 2012;54(5):381–9. (In Russ.)]Подгорный О. В., Лазарев В. Н., Говорун В. М. Лазерная микродиссекция в биологии и медицине. Цитология 2012;54(5):381–9. [Podgornyi O.V., Lazarev V.N., Govorun V.M. Laser dissection in biology and medicine. Tsitologiya = Cytology 2012;54(5):381–9. (In Russ.)]49. van Dam E. M., Robinson P. J. Ral: mediator of membrane trafficking. Int J Biochem Cell Biol 2006;38(11):1841–7.van Dam E. M., Robinson P. J. Ral: mediator of membrane trafficking. Int J Biochem Cell Biol 2006;38(11):1841–7.50. Xiong J., Liu1 J., Rayner S. et al. Protein-protein interaction reveals synergistic discrimination of cancer phenotype. Cancer Inform 2010;9:61–6.Xiong J., Liu1 J., Rayner S. et al. Protein-protein interaction reveals synergistic discrimination of cancer phenotype. Cancer Inform 2010;9:61–6.51. Neumann J., Wehweck L., Maatz S. et al. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. Virchows Arch 2013;463(4):509–23.Neumann J., Wehweck L., Maatz S. et al. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. Virchows Arch 2013;463(4):509–23.52. Герштейн Е. С., Кушлинский Н. Е. Факторы роста, их рецепторы и нижележащие сигнальные белки: от эксперимента к клинике. Успехи молекулярной онкологии 2014;(1):27–35. [Gershtein E. S., Kushlinsky N. E. Growth factors, their receptors and down-stream signaling proteins in human tumors: from experiment to clinical practice. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2014;(1):27–35. (In Russ.)].Герштейн Е. С., Кушлинский Н. Е. Факторы роста, их рецепторы и нижележащие сигнальные белки: от эксперимента к клинике. Успехи молекулярной онкологии 2014;(1):27–35. [Gershtein E. S., Kushlinsky N. E. Growth factors, their receptors and down-stream signaling proteins in human tumors: from experiment to clinical practice. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2014;(1):27–35. (In Russ.)].53. George K. S., Wu S. Lipid raft: A floating island of death or survival. Toxicol Appl Pharmacol 2012;259(3):311–9.George K. S., Wu S. Lipid raft: A floating island of death or survival. Toxicol Appl Pharmacol 2012;259(3):311–9.54. Chowdhury I., Thompson W. E., Thomas K. Prohibitins role in cellular survival through Ras–Raf–MEK–ERK pathway. J Cell Physiol 2014;229(8): 998–1004.Chowdhury I., Thompson W. E., Thomas K. Prohibitins role in cellular survival through Ras–Raf–MEK–ERK pathway. J Cell Physiol 2014;229(8): 998–1004.55. Sotgia F., Martinez-Outschoorn U. E., Howell A. et al. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 2012;7:423–67. doi: 10.1146 / annurevpathol-011811–120856.Sotgia F., Martinez-Outschoorn U. E., Howell A. et al. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 2012;7:423–67. doi: 10.1146 / annurevpathol-011811–120856.56. Arkhipova K. A., Sheyderman A. N., Laktionov K. K. et al. Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas. BMC Cancer 2014;14:100. doi: 10.1186 / 1471‑2407‑14‑100.Arkhipova K. A., Sheyderman A. N., Laktionov K. K. et al. Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomas. BMC Cancer 2014;14:100. doi: 10.1186 / 1471‑2407‑14‑100.57. Andreu Z., Yáñez-Mó M. Tetraspanins in extracellular vesicle formation and function. Front Immunol 2014;5:442. doi: 10.3389 / fimmu. 2014.00442.Andreu Z., Yáñez-Mó M. Tetraspanins in extracellular vesicle formation and function. Front Immunol 2014;5:442. doi: 10.3389 / fimmu. 2014.00442.58. Kaplan R., Rafii S., Lyden D. Preparing the “soil”: the premetastatic niche. Cancer Res 2006;66(23):11089–93.Kaplan R., Rafii S., Lyden D. Preparing the “soil”: the premetastatic niche. Cancer Res 2006;66(23):11089–93.59. Pant S., Hilton H., Burczynski M. E. The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol 2012;83(11):1484–94.Pant S., Hilton H., Burczynski M. E. The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol 2012;83(11):1484–94.60. Braicu C., Tomuleasa C., Monroig P. et al. Exosomes as divine messengers: are they the Hermes of modern molecular oncology?Cell Death Differ. 2014. doi: 10.1038 / cdd. 2014.130.Braicu C., Tomuleasa C., Monroig P. et al. Exosomes as divine messengers: are they the Hermes of modern molecular oncology?Cell Death Differ. 2014. doi: 10.1038 / cdd. 2014.130.61. Brabender J., Marjoram P., Salonga D. et al. Expression analysis of a limited number of highly selected genes may have clinical usefulness for the treatment of patients with this disease. A multigene expression panel for the molecular diagnosis of Barrett's esophagusand Barrett's adenocarcinoma of the esophagus. Oncogene 2004;23(27):4780–8.Brabender J., Marjoram P., Salonga D. et al. Expression analysis of a limited number of highly selected genes may have clinical usefulness for the treatment of patients with this disease. A multigene expression panel for the molecular diagnosis of Barrett's esophagusand Barrett's adenocarcinoma of the esophagus. Oncogene 2004;23(27):4780–8.62. Singhal S., Vachani A., Antin-Ozerkis D. et al. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005;1(11):3974–86.Singhal S., Vachani A., Antin-Ozerkis D. et al. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005;1(11):3974–86.63. Zhu C. Q., Shih W., Ling C. H, Tsao M. S. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006;59(8):790–800.Zhu C. Q., Shih W., Ling C. H, Tsao M. S. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006;59(8):790–800.64. Okayama H., Schetter A. J., Ishigame T. et al. The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts. Cancer Epidemiol Biomarkers Prev 2014. pii: cebp. 0182.2014.Okayama H., Schetter A. J., Ishigame T. et al. The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts. Cancer Epidemiol Biomarkers Prev 2014. pii: cebp. 0182.2014.65. Юдин Д. И. Молекулярно-биологические особенности опухоли в индивидуальном прогнозировании результатов хирургического лечения немелкоклеточного рака легкого, Дис. ... канд. мед. наук. М., 2005. 126 с. [Yudin D.I. Molecular and biological peculiarities of tumors in individual prediction of results of surgical treatment of non-small cells lung cancer: Thesis ...of candidate of medical sciences. Moscow, 2005. 126 p. (In Russ.)]Юдин Д. И. Молекулярно-биологические особенности опухоли в индивидуальном прогнозировании результатов хирургического лечения немелкоклеточного рака легкого, Дис. ... канд. мед. наук. М., 2005. 126 с. [Yudin D.I. Molecular and biological peculiarities of tumors in individual prediction of results of surgical treatment of non-small cells lung cancer: Thesis ...of candidate of medical sciences. Moscow, 2005. 126 p. (In Russ.)]66. Witta S. E., Gemmill R. M., Hirsch F. R. et al. Restoring e-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66(2):944–50.Witta S. E., Gemmill R. M., Hirsch F. R. et al. Restoring e-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66(2):944–50.67. Witta S. E., Jotte R. M., Konduri K. et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 2012;30(18):2248–55.Witta S. E., Jotte R. M., Konduri K. et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 2012;30(18):2248–55.68. Imyanitov E. N. Ovarian cancer genome. Methods Mol Biol 2013;1049:3–7. doi: 10.1007 / 978‑1‑62703‑547‑7_1.Imyanitov E. N. Ovarian cancer genome. Methods Mol Biol 2013;1049:3–7. doi: 10.1007 / 978‑1‑62703‑547‑7_1.69. Iyevleva A. G., Mitiushkina N. V., Karaseva N. A. et al. Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment. J Thorac Oncol. 2014;9(4):e31–3.Iyevleva A. G., Mitiushkina N. V., Karaseva N. A. et al. Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment. J Thorac Oncol. 2014;9(4):e31–3.70. Семиглазова Т. Ю., Клименко В. А., Филатова Л. В. и др. Маркеры эффективности предоперационной таксансодержащей химиотерапии местнораспространенного рака молочной железы. Вопросы онкологии 2013;59(3):363–7. [Semiglazova T.Yu., Klimenko V.A., Filatova L.V. et al. Markers of efficiency of preoperative taxanecontaining chemotherapy of locally advanced breast cancer. Voprosy onkologii = Oncology Issues 2013;59(3):363–7. (In Russ.)]Семиглазова Т. Ю., Клименко В. А., Филатова Л. В. и др. Маркеры эффективности предоперационной таксансодержащей химиотерапии местнораспространенного рака молочной железы. Вопросы онкологии 2013;59(3):363–7. [Semiglazova T.Yu., Klimenko V.A., Filatova L.V. et al. Markers of efficiency of preoperative taxanecontaining chemotherapy of locally advanced breast cancer. Voprosy onkologii = Oncology Issues 2013;59(3):363–7. (In Russ.)]71. Городнова Т. В., Максимов С. Я., Гусейнов К. Д., Имянитов Е. Н. Оценка эффективности платиносодержащей химиотерапии у больных раком яичников носительниц мутаций в гене BRCA1. Вопросы онкологии 2014;60(3):339–42. [Gorodnova .V., Maximov S.Ya., Guseinov C.D., Imyanitov E.N. Assessment of efficiency of platinum-containing chemotherapy of patients with ovarian carcinoma that carry mutations in the BRCA1 gene. Voprosy onkologii = Oncology Issues 2014;60(3):339-42. (In Russ.)]Городнова Т. В., Максимов С. Я., Гусейнов К. Д., Имянитов Е. Н. Оценка эффективности платиносодержащей химиотерапии у больных раком яичников носительниц мутаций в гене BRCA1. Вопросы онкологии 2014;60(3):339–42. [Gorodnova .V., Maximov S.Ya., Guseinov C.D., Imyanitov E.N. Assessment of efficiency of platinum-containing chemotherapy of patients with ovarian carcinoma that carry mutations in the BRCA1 gene. Voprosy onkologii = Oncology Issues 2014;60(3):339-42. (In Russ.)]72. Имянитов Е. Н. Меланома: от исследований молекулярного патогенеза к революции в лечении. Архив патологии 2013;75(5):63–72. [Imyanitov E.N. Melanoma: from research of molecular pathogenesis to revolution in therapy. Arkhiv patologii = Pathology Archive 2013;75(5):63–72. (In Russ.)]Имянитов Е. Н. Меланома: от исследований молекулярного патогенеза к революции в лечении. Архив патологии 2013;75(5):63–72. [Imyanitov E.N. Melanoma: from research of molecular pathogenesis to revolution in therapy. Arkhiv patologii = Pathology Archive 2013;75(5):63–72. (In Russ.)]73. Герштейн Е. С., Кушлинский Д. Н., Левкина Н. В. и др. Взаимосвязь экспрессии компонентов VEGF-сигнального пути и матриксных металлопротеиназ в опухолях больных с новообразованиями яичников. Бюллетень экспериментальной биологии и медицины 2011;151(4):431–6. [Gerstein E.S., Kushlinskiy D.N., Levkina N.V. et al. Interconnection between expression of components of VEGF signal route and matrix metalloproteinases in tumors of patients with ovarian neoplasms. Bulleten’ eksperimental’noy biologii I meditsiny = Bulletin of Experimental Biology and Medicine 2011;151(4):431–6. (In Russ.)]Герштейн Е. С., Кушлинский Д. Н., Левкина Н. В. и др. Взаимосвязь экспрессии компонентов VEGF-сигнального пути и матриксных металлопротеиназ в опухолях больных с новообразованиями яичников. Бюллетень экспериментальной биологии и медицины 2011;151(4):431–6. [Gerstein E.S., Kushlinskiy D.N., Levkina N.V. et al. Interconnection between expression of components of VEGF signal route and matrix metalloproteinases in tumors of patients with ovarian neoplasms. Bulleten’ eksperimental’noy biologii I meditsiny = Bulletin of Experimental Biology and Medicine 2011;151(4):431–6. (In Russ.)]74. Bogush T. A., Dudko E. A., Semakov A. V. et al. Immunofluorescent assay of ERCC1 and estimation ofclinical significance of the protein expression in ovarian cancer tissue. Dokl Biochem Biophys 2014;457(1):141–5.Bogush T. A., Dudko E. A., Semakov A. V. et al. Immunofluorescent assay of ERCC1 and estimation ofclinical significance of the protein expression in ovarian cancer tissue. Dokl Biochem Biophys 2014;457(1):141–5.75. Emelyanova M., Arkhipova K., Mazurenko N. et al. Sensitive Genotyping of Somatic Mutations in the EGFR, KRAS, PIK3CA, BRAF Genes from NSCLC Patients Using Hydrogel Biochips. Appl Immunohistochem Mol Morphol 2014. [Epub ahead of print].Emelyanova M., Arkhipova K., Mazurenko N. et al. Sensitive Genotyping of Somatic Mutations in the EGFR, KRAS, PIK3CA, BRAF Genes from NSCLC Patients Using Hydrogel Biochips. Appl Immunohistochem Mol Morphol 2014. [Epub ahead of print].76. Demidova I., Barinov A., Savelov N. et al. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of naplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls. Arch Pathol Lab Med 2014;38(6):794–802.Demidova I., Barinov A., Savelov N. et al. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of naplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls. Arch Pathol Lab Med 2014;38(6):794–802.77. Blom R. L., Bogush T., Brücher B. L. et al. Therapeutic approaches to gastroesophageal junction adenocarcinomas. Ann NY Acad Sci 2014;1325(1):197–210.Blom R. L., Bogush T., Brücher B. L. et al. Therapeutic approaches to gastroesophageal junction adenocarcinomas. Ann NY Acad Sci 2014;1325(1):197–210.78. de Thé H., Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010;10(11):775–83.de Thé H., Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010;10(11):775–83.79. Grosse-Gehling P., Fargeas C. A., Dittfeld C. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol 2013;229(3):355–78.Grosse-Gehling P., Fargeas C. A., Dittfeld C. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol 2013;229(3):355–78.80. Roudi R., Madjd Z., Korourian A. et al. Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer. Cancer Biomark 2014;14(6):457–67. doi: 10.3233 / CBM-140424.Roudi R., Madjd Z., Korourian A. et al. Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer. Cancer Biomark 2014;14(6):457–67. doi: 10.3233 / CBM-140424.81. Bertolini G., Roz L., Perego P. et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009;106(38):16281–6.Bertolini G., Roz L., Perego P. et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009;106(38):16281–6.82. Sun Q. L., Sha H. F., Yang X. H. et al. Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549‑Taxol. J Cancer Res Clin Oncol 2011;137(3):521–32.Sun Q. L., Sha H. F., Yang X. H. et al. Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549‑Taxol. J Cancer Res Clin Oncol 2011;137(3):521–32.83. Alamgeer M., Ganju V., Kumar B. Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Res 2014;16(2):R44. doi: 10.1186 / bcr3648.Alamgeer M., Ganju V., Kumar B. Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Res 2014;16(2):R44. doi: 10.1186 / bcr3648.84. Shtam T. A., Kovalev R. A., Varfolomeeva E. Y. et al. Exosomes are natural carriers of xogenous siRNA to human cells in vitro. Cell Commun Signal 2013;11:88. doi: 10.1186 / 1478-811X-11–88.Shtam T. A., Kovalev R. A., Varfolomeeva E. Y. et al. Exosomes are natural carriers of xogenous siRNA to human cells in vitro. Cell Commun Signal 2013;11:88. doi: 10.1186 / 1478-811X-11–88.85. Ling H., Fabbri M., Calin G. A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nature reviews. Drug Discov 2013;12(11):847–65.Ling H., Fabbri M., Calin G. A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nature reviews. Drug Discov 2013;12(11):847–65.86. Li S., Liang Z., Xu L., Zou F. MicroRNA-21: a ubiquitously expressed prosurvival factor in cancer and other diseases. Mol Cell Biochem 2012;360(1–2):147–58.Li S., Liang Z., Xu L., Zou F. MicroRNA-21: a ubiquitously expressed prosurvival factor in cancer and other diseases. Mol Cell Biochem 2012;360(1–2):147–58.87. Shevchenko V., Kovalev S., Arnotskaya N. et al. Human blood plasma proteome mapping for search of potential markers of the lung squamous cell carcinoma. Eur J Mass Spectrometry 2013;19(2):123–33.Shevchenko V., Kovalev S., Arnotskaya N. et al. Human blood plasma proteome mapping for search of potential markers of the lung squamous cell carcinoma. Eur J Mass Spectrometry 2013;19(2):123–33.88. Bridge J. A., Cushman-Vokoun A. M. Molecular diagnostics of soft tissue tumors. Arch Pathol Lab Med 2011;135(5):588–601.Bridge J. A., Cushman-Vokoun A. M. Molecular diagnostics of soft tissue tumors. Arch Pathol Lab Med 2011;135(5):588–601.89. Nookaew I., Papini M., Pornputtapong N. et al. A comprehensive comparison of RNA-Seq-based transcriptome analysis from reads to differential gene expression and crosscomparison with microarrays: a case study in Saccharomyces cerevisiae. Nucleic Acids Res 2012;40(20):10084–97.Nookaew I., Papini M., Pornputtapong N. et al. A comprehensive comparison of RNA-Seq-based transcriptome analysis from reads to differential gene expression and crosscomparison with microarrays: a case study in Saccharomyces cerevisiae. Nucleic Acids Res 2012;40(20):10084–97.90. Marjanovic N. D., Weinberg R. A., Chaffer C. L. Cell plasticity and heterogeneity in cancer. Clin Chem 2013;59(1):168–79.Marjanovic N. D., Weinberg R. A., Chaffer C. L. Cell plasticity and heterogeneity in cancer. Clin Chem 2013;59(1):168–79.91. Griffiths-Jones S., Grocock R. J., van Dongen S. et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006;34(Database issue): D140–4.Griffiths-Jones S., Grocock R. J., van Dongen S. et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006;34(Database issue): D140–4.92. Kozomara A., Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011;39(Database issue):D152–7.Kozomara A., Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011;39(Database issue):D152–7.